Issues with continuation of DMT treatment Situation in country of interest? World Bank category Upper middle income WHO region European Global results
% of countries reporting issues with continuation of DMT treatment
Yes – irregular DMT supply to the country data not known 46% 12% 27%
Yes – tests required to prove continued eligibility data not known 7% 10% 13%
Yes – DMT reimbursement needs to renew at regular intervals data not known 25% 15% 19%
Yes – people are only allowed DMTs for a limited amount of time (e.g. 2 years) data not known 14% 2% 6%
Yes – for a different reason data not known 11% 5% 14%
No issues with continuation of treatment data not known 39% 66% 44%
Not sure data not known 0% 2% 9%
Any treatment continuation issues No 61% 32% 48%

What is the Atlas of MS?

The Atlas of MS is the most comprehensive worldwide study of the epidemiology of MS and the global availability and accessibility of resources for people with MS.

Explore the latest MS data

Access the latest Atlas of MS reports, infographics, slides and datasets to support research, advocacy and policy development. Planning an analysis or publication? Contact the Atlas team at [email protected] for guidance on methodology, data interpretation and related work.

Powerful tool for change

The information in the Atlas of MS can be a powerful advocacy tool, shining a spotlight on MS and raising awareness of the lack of adequate resources available to diagnose, inform, treat, rehabilitate and support people with MS worldwide.

With thanks to…

Worldwide collaboration

The Atlas of MS relies on data supplied by MS organisations from around the world. We are most grateful to the country coordinators and their colleagues for taking the time and effort to gather the information and data.

See contributor list

The Atlas of MS is one of the strongest examples of what the global MS movement can achieve through collaboration. By bringing together evidence from countries around the world, it helps inform policy, strengthen advocacy and guide future investment in research and healthcare. The Atlas also highlights the need for continued investment in surveillance, registries and data systems to strengthen our understanding of the true burden of MS. Better data lead to better decisions and, ultimately, better outcomes for people affected by MS worldwide.

Professor Mario Alberto Battaglia
Chair, MS International Federation (MSIF) and President of the Italian MS Society (Associazione Italiana Sclerosi Multipla [AISM])